Primary localized cutaneous amyloidosis (PLCA) is a rare skin disorder characterized by the deposition of amyloid proteins in the dermis and epidermis. These abnormally structured proteins are formed from abnormally folded fibrillar proteins and result in the formation of localized amyloid plaques. The most commonly affected areas of the skin are the upper back, chest, face, and extremities. The disease appears as itchy, painless, firm plaques that may be yellowish-brown in color. PLCA is usually benign and does not cause systemic manifestations, but can have a significant impact on the patient's quality of life due to the unsightly appearance of the skin.
History of the disease and interesting historical facts
The first evidence of cutaneous amyloidosis was documented in the 19th century, but the disease itself began to be actively studied only in the 20th century. One of the first researchers to describe amyloidosis was the German pathologist Gustav Recklinghausen in 1873. His works noted that amyloidosis is the result of chronic inflammatory processes. In the following decades, researchers began to combine data on cutaneous manifestations with systemic forms of amyloidosis, identifying primary localized cutaneous amyloidosis as an independent nosological unit. Interesting historical facts include the use of comparative analysis with other dermatoses to identify key diagnostic criteria, which improved diagnostics and timely patient referral for medical care.
Epidemiology
The epidemiology of primary localized cutaneous amyloidosis remains poorly understood. There is evidence that the incidence of this condition varies by geographic region and ethnic group. Overall, the incidence of PLCA in the population is approximately 1-5 cases per 100,000 people annually. However, it should be noted that the incidence of this disease may be underestimated due to a lack of awareness among both patients and physicians. There is also an age predisposition of 50-70 years, with women being more common among patients. This information highlights the importance of raising awareness of the disease to ensure timely diagnosis and treatment of patients.
Genetic predisposition to this disease
Studies suggest that primary localized cutaneous amyloidosis may have a genetic predisposition, although currently identified mutations cannot be considered major risk factors. Some evidence suggests possible involvement of genes involved in immune response and protein structuring, such as the APOE gene, which has been associated with various protein abnormalities. Some estimates suggest that there may be a high incidence of the disease in certain families, suggesting a hereditary effect. However, specific mutations associated exclusively with PLCA have not yet been described, and more research is needed to fully understand the genetic basis of the disease.
Risk factors for the development of this disease
Among the risk factors that contribute to the development of primary localized cutaneous amyloidosis, the following can be distinguished:
- Chronic inflammation and dermatological diseases such as psoriasis and eczema.
- Age - most often, people of mature and elderly age are susceptible to the disease.
- Genetic predisposition - having a family history of the disease may increase the risk.
- Obesity and metabolic disorders that may affect metabolism and protein synthesis.
- General conditions associated with increased vascular permeability and protein deposition, such as chronic renal failure.
Understanding these risk factors is an important tool in the prevention and early diagnosis of PLA.
Diagnosis of this disease
Diagnosis of primary localized cutaneous amyloidosis is based on clinical examination, as well as confirmation of the diagnosis using laboratory and instrumental methods. The main symptoms include:
- Presence of asymptomatic or itchy amyloid plaques on the skin.
- Change in skin color in the area of the plaques - they often have a yellowish-brown tint.
Laboratory tests may include skin biopsy followed by histologic analysis to detect amyloid deposits. Radiologic tests are not specific for PLCA but can be used to rule out systemic amyloidosis. The differential diagnosis includes ruling out other skin conditions such as psoriasis, warts, and other forms of dermatoses.
Treatment
Treatment of primary localized cutaneous amyloidosis is aimed at relieving symptoms and improving the aesthetic appearance of the skin. General treatment may include:
- Local therapy - the use of corticosteroids to reduce inflammation and itching.
- Laser techniques such as laser photocoagulation to reduce the appearance of plaques.
- General skin care measures and use of moisturizers.
Pharmacological treatment may include the use of the drug obritezumab, which is aimed at reducing the formation of amyloid. Surgery may be recommended in cases of severe cosmetic defect or to remove large plaques. Physical therapy procedures, including cryotherapy, are considered as an alternative treatment, which can help reduce skin manifestations.
List of medications used to treat this disease
Drugs used to treat primary localized cutaneous amyloidosis include:
- Glucocorticosteroids - local and systemic.
- Immunosuppressants - such as azathioprine.
- Topical retinoids.
- Phototherapy drugs - such as psoralen with UVA.
- Monoclonal antibodies aimed at the treatment of generalized forms of amyloidosis.
These drugs can be used depending on the individual characteristics of the course of the disease and the patient's condition.
Disease monitoring
Monitoring of primary localized cutaneous amyloidosis includes regular monitoring of the skin condition and evaluation of the effectiveness of the treatment. Control stages are usually carried out every 3-6 months. The prognosis for patients with PLCA is generally favorable, since the disease has a benign course and does not lead to systemic complications. However, in rare cases, progression to a generalized form of amyloidosis can be observed, which requires careful monitoring. Complications can be determined by concomitant skin infections or secondary dermatitis.
Age-related features of the disease
Primary localized cutaneous amyloidosis can occur in various age groups, but the greatest number of cases are associated with elderly patients, mainly aged 50-70 years. In children and adolescents, the disease is extremely rare, and, as a rule, has a milder course. Elderly patients have a greater predisposition to developing the disease due to age-related changes in the dermis and related factors, such as chronic inflammation.
Questions and Answers
- What is primary localized cutaneous amyloidosis? This is a rare disease characterized by the deposition of amyloid proteins in the upper layers of the skin, which manifests itself as the formation of dense plaques.
- What are the main symptoms of PLA? The main symptoms include the presence of painless or itchy plaques on the skin, colored yellowish-brown, most often located on the back and limbs.
- Who is most susceptible to this disease? The disease is most common in older people, primarily women aged 50-70 years, but it can also occur in younger patients, but less frequently.
- How is PLCA diagnosed? Diagnosis includes clinical examination, skin biopsy with histological analysis and exclusion of other dermatological diseases.
- What treatment is recommended for PLCA? Treatment may include the use of corticosteroids, laser procedures, topical retinoids, and, in some cases, surgery to remove large plaques.
